Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|January 13, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-02-03-2016
- Volume 12
- Issue 2
Catalent Biologics and Roche Announce Research Collaboration
Author(s)Pharmaceutical Technology Editors
The collaboration will focus on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Advertisement
On Jan. 13, 2016 Catalent Biologics and Roche announced a collaboration to develop molecules coupling different therapeutic modalities using SMARTag technology, Catalent’s programmable protein-modification platform. According to the a press announcement from the companies,
Roche will gain non-exclusive access to the SMARTag platform and will have an option to take commercial licenses to develop molecules.The SMARTag platform will be combined with the hydrazino-Pictet-Spengler (HIPS) conjugation platform and will permit evaluation of alternative sites of drug conjugation.
Roche will pay Catalent an up-front fee of $1 million and provide additional research funding during the initial phase of the collaboration. Catalent has the potential to receive up to $618 million in development and commercial milestones, plus royalties on net sales of products, if Roche pursues commercial licenses and all options are exercised.
Source:
Articles in this issue
over 10 years ago
Is Consolidation Good for Pharma?over 10 years ago
Parenteral Packagers Focus on Security and Supply-Chain Transparencyover 10 years ago
Hermes Pharma Adds Hot Melt Coating Capabilityover 10 years ago
Novasep Adds Small-Scale Manufacturing Capability to US Facilityover 10 years ago
Vetter Completes Development and IT Facilityover 10 years ago
Adents, Siemens Team on Serialization Solutionover 10 years ago
Onyx Scientific Announces Facility Expansionover 10 years ago
FDA’s CDER Previews 2016 Guidance AgendaAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Advertisement
Advertisement